SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549


                                   FORM 8-A/A


                               (Amendment No. 1)

               FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
                   PURSUANT TO SECTION 12(b) OR 12(g) OF THE
                        SECURITIES EXCHANGE ACT OF 1934

                          ENZON PHARMACEUTICALS, INC.
             (Exact name of registrant as specified in its charter)


                 Delaware                                        22-2372868
  --------------------------------------                    --------------------
     (State or other jurisdiction of                          (I.R.S. Employer
      incorporation or organization)                        Identification No.)

685 Route 202/206, Bridgewater, New Jersey                         08807
- ------------------------------------------                    ---------------
 (Address of principal executive offices)                        (Zip Code)


If this form relates to the                  If this form relates to the
registration of a class of                   registration of a class of
securities pursuant to Section               securities pursuant to Section
12(b) of the Exchange Act and is             12(g)of the Exchange Act and is
effective upon filing pursuant to            effective pursuant to General
General Instruction A.(c), please            Instruction A.(d), please check the
check the following box. [ ]                 following box. [X]

Securities Act registration statement file numbers to which this form relates:
000-12957

Securities to be registered pursuant to Section 12(b) of the Act:

       Title of Each Class                        Name of Each Exchange
       to Be So Registered               on Which Each Class Is to Be Registered
- ---------------------------------        ---------------------------------------
               N/A                                         N/A

Securities to be registered pursuant to Section 12(g) of the Act:

                    Series B Preferred Stock Purchase Rights
                                (Title of Class)



         This Amendment No. 1 on Form 8-A/A amends and supplements Item 1 and
Item 2 of the Registration Statement on Form 8-A (the "Registration Statement")
filed by Enzon Pharmaceuticals, Inc., formerly known as Enzon, Inc., a Delaware
corporation ("Enzon"), with the Securities and Exchange Commission (the
"Commission") on May 22, 2002 (File No. 000-129570), which was filed in
connection with Enzon's adoption of a Rights Agreement, dated as of May 17, 2002
(the "Rights Plan"). Except as amended hereby, there are no other changes to the
Registration Statement.



Item 1.  Description of Registrant's Securities to be Registered.

         Item 1 of the Registration Statement is hereby amended to add the
following paragraphs at the end thereof:

         Pursuant to the First Amendment to the Rights Agreement, dated as of
February 19, 2003 (the "Amendment"), Enzon amended the Rights Plan to provide
that (i) each of Momentum Merger Corporation ("Holdco") and NPS Pharmaceuticals,
Inc. ("NPS") and any of their respective Affiliates or Associates, as such terms
are defined in the Rights Plan, would be deemed an "Exempt Person", as such term
is defined in the Rights Plan and neither the "Shares Acquisition Date" nor the
"Distribution Date", as each such term is defined in the Rights Plan, would be
deemed to occur, in each such case, by the approval, execution or delivery of,
or consummation of the transactions contemplated under, the Agreement and Plan
of Reorganization dated as of February 19, 2003, by and among Enzon, Holdco,
Einstein Acquisition Corp., Newton Acquisition Corp. and NPS (the "Merger
Agreement"), and (ii) because the rights are evidenced by shares of Enzon Common
Stock, all outstanding rights will terminate upon the effective time of the
Merger when shares of Enzon Common Stock will be exchanged for a number of
shares of Holdco Common Stock. By its own terms, the Amendment shall be deemed
to be in force and effect immediately prior to the execution and delivery of the
Merger Agreement.

         The Amendment is attached hereto as Exhibit 2 and is incorporated
herein by reference. The foregoing description of the Amendment does not purport
to be complete and is qualified in its entirety by such Exhibit.

Item 2.  Exhibits.

    Exhibit No.     Description
    -----------     -----------

         1        Rights Agreement dated as of May 17, 2002 ("Rights Agreement")
                  between the Company and Continental Stock Transfer & Trust
                  Company, as Rights Agent.*

         2        First Amendment to Rights Agreement, dated as of May 17, 2002,
                  between Enzon and Continental Stock Transfer & Trust Company,
                  as rights agent, dated as of February 19, 2003.**

         3        Form of Right Certificate (filed as Exhibit B to the Right
                  Agreement). Pursuant to the Rights Agreement, printed Right
                  Certificates will not be mailed until the Distribution Date
                  (as defined in the Rights Agreement).*

         4        Summary of Rights (filed as Exhibit C to the Rights
                  Agreement).*

         5        Form of Certificate of Designation with respect to the Series
                  B Preferred Stock, par value $.01 per share, of the Company
                  (filed as Exhibit A to the Rights Agreement)*

*  Incorporated herein by reference to the Exhibits to the Form 8-A filed on
   May 22, 2002.

** Filed herewith.



                                   SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of
1934, the Registrant has duly caused this Amendment No. 1 to the Registration
Statement to be signed on its behalf by the undersigned, thereto duly
authorized.

Date: February 20, 2003                      Enzon Pharmaceuticals, Inc.

                                             /s/ Arthur J. Higgins
                                             -----------------------------------
                                                  Arthur J. Higgins
                                                  Chief Executive Officer




                                                                       Exhibit 2


                    FIRST AMENDMENT TO THE RIGHTS AGREEMENT

         First Amendment (the "Amendment"), dated as of February 19, 2003,
between Enzon Pharmaceuticals, Inc. (formerly, Enzon, Inc.), a Delaware
corporation (the "Company"), and Continental Stock Transfer & Trust Company, as
rights agent (the "Rights Agent"), to the Rights Agreement dated as of May 17,
2002 (the "Rights Agreement"); capitalized terms used without definition in this
Amendment shall have the meanings given to them in the Rights Agreement.

         WHEREAS, pursuant to Section 27 of the Rights Agreement, the Company
and the Rights Agent may from time to time supplement and amend the Rights
Agreement in order to make any changes which the Company may deem necessary or
desirable;

         WHEREAS, the Board of Directors of the Company has determined that an
amendment is necessary and desirable, and the Company and the Rights Agent
desire to evidence such amendment in writing;

         WHEREAS, the Company and NPS Pharmaceuticals, Inc. (as defined below)
shall enter into the Merger Agreement (as defined below), pursuant to which,
among other things, the Company and NPS Pharmaceuticals, Inc. shall effect a
business combination; and

         WHEREAS, no Person (as defined in the Rights Agreement) is an Acquiring
Person (as defined in the Rights Agreement and as amended below) as of the date
hereof.

         NOW THEREFORE, the parties hereto agree as follows:

         1.       Amendment to Section 1 (Certain Definitions).
                  ---------------------------------------------

                  (a)      The definition of "Exempt Person" in Section 1 of the
Rights Agreement is hereby amended by replacing the words "and (vi)" with the
following:

         "(vi) Holdco (as such term is hereinafter defined) or NPS (as such term
         is hereinafter defined) or any of their respective Affiliates or
         Associates, solely in connection with the approval, execution or
         delivery of, or consummation of the transactions contemplated under,
         the Agreement and Plan of Reorganization dated as of February 19, 2003
         (the "Merger Agreement) by and among the Company, Momentum Merger
         Corporation ("Holdco"), Einstein Acquisition Corporation ("Merger
         Sub"), Newton Acquisition Corporation and NPS Pharmaceuticals, Inc.
         ("NPS"), pursuant to which the Company (after giving effect to its
         merger with and into Merger Sub) and NPS would become wholly-owned
         subsidiaries of Holdco, as more fully described therein, as the Merger
         Agreement may be amended from time to time in accordance with its
         terms, and (vii)"

                  (b)      The definition of "Exempt Person" in Section 1 of the
Rights Agreement is hereby amended by replacing the words "under this clause
(vi)" with the following:

         "under this clause (vii)"



                  (c)      The definition of "Shares Acquisition Date" in
Section 1 of the Rights Agreement is hereby amended by adding the following
sentence at the end thereof:

         "Notwithstanding anything in this Agreement to the contrary, a Shares
Acquisition Date shall not be deemed to have occurred solely in connection with
the approval, execution or delivery of, or consummation of the transactions
contemplated, under the Merger Agreement"

         2.       Amendment to Section 3 (Issue of Right Certificates). Section
3(a) of the Rights Agreement is hereby amended by inserting the following
sentence immediately after the last sentence thereof:

         "Notwithstanding anything in this Agreement to the contrary, a
         Distribution Date shall not be deemed to have occurred solely by reason
         of the approval, execution or delivery of, or consummation of the
         transactions contemplated by, the Merger Agreement, as the Merger
         Agreement may be amended from time to time in accordance with its
         terms"

         3.       Amendment to Section 7 (Exercise of Right; Purchase Price;
Expiration Date of Rights). Section 7(a) of the Rights Agreement is hereby
amended by inserting the following words between the words "prior to the
earliest of the Final Expiration Date," and "the Redemption Date":

         "the Effective Time (as defined in the Merger Agreement),"

         4.       Amendment to Section 29 (Benefits of Agreement; No Liability).
Section 29 of the Rights Agreement is hereby amended by inserting the following
sentence immediately after the last sentence thereof:

         "Nothing in this Agreement shall be construed to give any holder of
         Rights or any other Person any legal or equitable rights, remedies or
         claims under this Agreement by virtue of the execution of the Merger
         Agreement or the consummation of the transactions contemplated by the
         Merger Agreement."

         5.       Effectiveness. This Amendment shall be deemed to be in force
and effect immediately prior to the execution and delivery of the Merger
Agreement. Except as amended hereby, the Rights Agreement shall remain in full
force and effect and shall be otherwise unaffected hereby.

         6.       Counterparts. This Amendment may be executed in any number of
counterparts and each of such counterparts shall together constitute but one and
the same instrument.


                                      -2-


         7.       Miscellaneous. This Amendment shall be deemed a contract made
under the laws of Delaware and for all purposes shall be governed by and
construed in accordance with the laws of such state. If any term or other
provision of this Amendment is determined to be invalid, illegal or incapable of
being enforced by any rule of law or public policy, all other terms and
provisions of this Amendment shall nevertheless remain in full force and effect
and upon such determination that any term or other provision is invalid, illegal
or incapable of being enforced, this Amendment and such term or other provision
shall be deemed to have been amended so as to effect the original intent of the
parties as closely as possible in an acceptable manner to the Board of Directors
of the Company.


                    [REST OF PAGE INTENTIONALLY LEFT BLANK]


                                      -3-


         IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
duly executed and attested, all as of the day and year first written above.


                                             ENZON PHARMACEUTICALS, INC.

Attest:

By: /s/ Kenneth J. Zuerblis                  By: /s/ Arthur J. Higgins
   --------------------------------             --------------------------------
Name:  Kenneth J. Zuerblis                   Name:  Arthur J. Higgins
Title: Chief Financial Officer               Title: Chief Executive Officer


                                             CONTINENTAL STOCK TRANSFER &
                                              TRUST COMPANY, as Rights Agent

Attest:
By:/s/ Tuulikki Huovinen                     By:/s/ Roger T. Bernhammer
   --------------------------------             --------------------------------
Name:  Tuulikki Huovinen                     Name:  Roger T. Bernhammer
Title: Assistant Secretary                   Title: Vice President


                                      -4-